Literature DB >> 34791396

Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.

Rachel Bernard1, Suchitra K Hourigan2, Maribeth R Nicholson1.   

Abstract

Clostridioides difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea and has high rates of recurrent disease. As a disease associated with intestinal dysbiosis, gastrointestinal microbiome manipulation and fecal microbiota transplantation (FMT) have evolved as effective, although relatively unregulated therapeutics and not without safety concerns. FMT for the treatment of CDI has been well studied in adults with increasing data reported in children. In this review, we discuss the current body of literature on the use of FMT in children including effectiveness, safety, risk factors for a failed FMT, and the role of FMT in children with comorbidities. We also review emerging microbial therapeutics for the treatment of rCDI.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  fecal microbiota transplantation; fecal transplantation; pediatric Clostridioides difficile

Mesh:

Year:  2021        PMID: 34791396      PMCID: PMC8600035          DOI: 10.1093/jpids/piab056

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   5.235


  46 in total

1.  Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea.

Authors:  Ju Young Chang; Dionysios A Antonopoulos; Apoorv Kalra; Adriano Tonelli; Walid T Khalife; Thomas M Schmidt; Vincent B Young
Journal:  J Infect Dis       Date:  2008-02-01       Impact factor: 5.226

2.  Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

Authors:  Christine H Lee; Theodore Steiner; Elaine O Petrof; Marek Smieja; Diane Roscoe; Anouf Nematallah; J Scott Weese; Stephen Collins; Paul Moayyedi; Mark Crowther; Mark J Ropeleski; Padman Jayaratne; David Higgins; Yingfu Li; Neil V Rau; Peter T Kim
Journal:  JAMA       Date:  2016-01-12       Impact factor: 56.272

3.  Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile.

Authors:  Julia L Drewes; Alina Corona; Uriel Sanchez; Yunfan Fan; Suchitra K Hourigan; Melissa Weidner; Sarah D Sidhu; Patricia J Simner; Hao Wang; Winston Timp; Maria Oliva-Hemker; Cynthia L Sears
Journal:  JCI Insight       Date:  2019-10-03

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

5.  The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients.

Authors:  Yifei Chen; Liangjun Chen; Qiaoling Deng; Guqin Zhang; Kaisong Wu; Lan Ni; Yibin Yang; Bing Liu; Wei Wang; Chaojie Wei; Jiong Yang; Guangming Ye; Zhenshun Cheng
Journal:  J Med Virol       Date:  2020-04-25       Impact factor: 2.327

6.  Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.

Authors:  Colleen R Kelly; Chioma Ihunnah; Monika Fischer; Alexander Khoruts; Christina Surawicz; Anita Afzali; Olga Aroniadis; Amy Barto; Thomas Borody; Andrea Giovanelli; Shelley Gordon; Michael Gluck; Elizabeth L Hohmann; Dina Kao; John Y Kao; Daniel P McQuillen; Mark Mellow; Kevin M Rank; Krishna Rao; Arnab Ray; Margot A Schwartz; Namita Singh; Neil Stollman; David L Suskind; Stephen M Vindigni; Ilan Youngster; Lawrence Brandt
Journal:  Am J Gastroenterol       Date:  2014-06-03       Impact factor: 10.864

Review 7.  Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection.

Authors:  Y-T Li; H-F Cai; Z-H Wang; J Xu; J-Y Fang
Journal:  Aliment Pharmacol Ther       Date:  2015-12-14       Impact factor: 8.171

8.  Human gut microbiome viewed across age and geography.

Authors:  Tanya Yatsunenko; Federico E Rey; Mark J Manary; Indi Trehan; Maria Gloria Dominguez-Bello; Monica Contreras; Magda Magris; Glida Hidalgo; Robert N Baldassano; Andrey P Anokhin; Andrew C Heath; Barbara Warner; Jens Reeder; Justin Kuczynski; J Gregory Caporaso; Catherine A Lozupone; Christian Lauber; Jose Carlos Clemente; Dan Knights; Rob Knight; Jeffrey I Gordon
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

9.  Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies.

Authors:  Suresh Paudel; Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

10.  Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis.

Authors:  Simon Mark Dahl Baunwall; Mads Ming Lee; Marcel Kjærsgaard Eriksen; Benjamin H Mullish; Julian R Marchesi; Jens Frederik Dahlerup; Christian Lodberg Hvas
Journal:  EClinicalMedicine       Date:  2020-11-23
View more
  2 in total

Review 1.  Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study.

Authors:  Mancai Wang; Xiaofeng Xie; Songbo Zhao; Wei Han; Youcheng Zhang
Journal:  Front Microbiol       Date:  2022-08-18       Impact factor: 6.064

Review 2.  Effect of Traditional Chinese Medicine on Treating Antibiotic-Associated Diarrhea in Children: A Systematic Review and Meta-Analysis.

Authors:  Shunlian Fu; Lisha Sun; Yiding Chen; Qian Zhou; Lijun Yuan; Zinan Li; Qiu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-22       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.